CTLA4 fusion proteins for the treatment of diabetes
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
1. A method of treating type 1 diabetes mellitus in a subject comprising administering an effective amount of a fusion protein composition which comprises a fusion protein and an oil-based carrier, wherein the fusion protein comprises the extracellular domain of CTLA4 and a portion of an immunoglobulin molecule, and wherein the oil-based carrier is a water-in-oil emulsion.
2. The method of claim 1 wherein the composition comprises Abatacept.
3. The method of claim 1 wherein the composition is administered as a pharmaceutically acceptable salt.
4. The method of claim 1 , wherein the composition is administered by intravenous infusion.
5. The method of claim 4 , wherein the composition is administered by intravenous infusion in about 50 to 200 ml of physiological saline.
6. The method of claim 4 , wherein the composition is administered at a dose ranging from about 5 mg/kg to about 50 mg/kg.
7. The method of claim 4 , wherein the intravenous infusion of the composition is repeated over time.
8. The method of claim 4 , wherein the intravenous infusion of the composition is repeated at least once following a time interval ranging from about one week to about two months.
9. The method of claim 4 , wherein the composition is administered at a dose ranging from about 250 to 2000 mg.
10. The method of claim 9 , wherein the composition is administered at a dose of 500 mg.
11. The method of claim 9 , wherein the composition is administered at a dose of 750 mg.
12. The method of claim 9 , wherein the composition is administered at a dose of 1000 mg.
13. The method of claim 1 , wherein the subject is white.